Laekna, Inc. (HKG:2105)
Hong Kong · Delayed Price · Currency is HKD 13.93
+0.62 (4.66%)
At close: May 7, 2026
Laekna Revenue
In the year 2025, Laekna had annual revenue of 106.72M CNY. Laekna had revenue of 102.21M in the half year ending December 31, 2025.
Revenue
106.72M CNY
Revenue Growth
n/a
P/S Ratio
47.13
Revenue / Employee
1.29M CNY
Employees
83
Market Cap
5.60B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.72M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 280.00K | 169.00K | 152.25% |
| Dec 31, 2021 | 111.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.41B |
| Qyuns Therapeutics | 897.99M |
| Ocumension Therapeutics | 895.09M |
| Shandong Boan Biotechnology | 873.36M |
| Abbisko Cayman | 681.17M |
| Guangzhou Innogen Pharmaceutical Group | 146.34M |
| Jacobio Pharmaceuticals Group | 59.56M |
| Shanghai Bao Pharmaceuticals | 54.70M |